List of Evoclin drug patents

Evoclin is owned by Mylan.

Evoclin contains Clindamycin Phosphate.

Evoclin has a total of 2 drug patents out of which 0 drug patents have expired.

Evoclin was authorised for market use on 22 October, 2004.

Evoclin is available in aerosol, foam;topical dosage forms.

Evoclin can be used as treatment of acne vulgaris.

The generics of Evoclin are possible to be released after 03 February, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747 MYLAN Pharmaceutical foam
Jan, 2024

(11 months from now)

US7141237 MYLAN Pharmaceutical foam
Feb, 2024

(a year from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 22 October, 2004

Treatment: Treatment of acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of EVOCLIN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic